Bausch + Lomb posts strong third quarter results, raises full-year guidance. Thursday, October 29, 2026 12:27 AM VAUGHAN, Ontario - Global eye health company Bausch + Lomb Corporation (NYSE/TSX: BLCO) yesterday reported its third-quarter financial results. The company generated $1.375 billion in total revenue for Q3 2026, marking a 7 percent ($94 million) gain from $1.281 billion in Q3 2025, driven by what they said was revenue expansion in all three business segments. Excluding the unfavorable impact of foreign exchange of $6 million, revenue increased by approximately 8 percent on a constant currency basis compared with the third quarter of 2025. The company's Vision Care segment revenue grew by 5 percent, or 6 percent on a constant currency basis. "Our third-quarter performance reflects the strength and breadth of the business, with growth across all three segments and continued expansion in profitability," said Thomas J. Appio, chairman and interim CEO, Bausch + Lomb. "We have delivered against the commitments outlined at Investor Day for four consecutive quarters, and I believe there are additional opportunities to improve execution, enhance profitability and create even more value over time." Appio, who serves as chairman of the Bausch + Lomb board of directors and CEO of Bausch Health, (NYSE/TSX: BHC) took the helm as interim CEO of Bausch + Lomb on October 12. Appio was appointed chairman of the Bausch + Lomb board of directors in August 2026 and continues to serve as CEO of Bausch Health. "I want to say how honored and energized I am to serve as interim CEO of Bausch + Lomb," Appio said on yesterday's conference call. "Having spent a good part of my career with the company, I have developed a deep understanding of our business, our markets, our products, and most importantly, the exceptional global team that will drive our success. That experience gives me confidence in the strength of our organization, the trust our customers and patients place in us and our ability to execute against our priorities. I am excited to lead Bausch + Lomb to its next phase of growth and value creation." Growth Across All Segments Vision Care segment revenue was $774 million for the third quarter of 2026, as compared with $736 million for the third quarter of 2025, an increase of $38 million, or 5 percent, the company reported. Excluding an unfavorable impact of foreign exchange of $5 million, segment revenue increased on a constant currency basis by approximately 6 percent compared with the third quarter of 2025. Consumer sales of Lumify and Artelac, along with expansion in the daily SiHy and Ultra contact lens lines, served as the primary drivers of performance. Daily SiHy revenue growth reached 25 percent in Q3, the company advised, while Lumify generated a 35 percent revenue gain during the quarter. Overall segment sales in the U.S. rose by 9 percent. "What stands out to me about our contact lens business is the strong performance of the total portfolio, led by SiHy daily and monthly lenses," Appio said on the conference call. "Our daily SiHy portfolio grew 25 percent on a constant currency basis in the quarter, building on sustained growth across our contact lens offerings. That consistently speaks to the strength and durability of the business, one that I always thought was an underappreciated business." Surgical segment revenue was $234 million for the third quarter of 2026, compared with $215 million for the third quarter of 2025, an increase of $19 million, or 9 percent, the company reported. Excluding the unfavorable impact of foreign exchange of $1 million, segment revenue increased on a constant currency basis by approximately 9 percent compared with the third quarter of 2025. Performance was primarily driven by growth in the premium IOL portfolio, which saw a 70 percent increase in revenue year-over-year. Pharmaceuticals segment revenue was $367 million for the third quarter of 2026, compared with to $330 million for the third quarter of 2025, an increase of $37 million, or 11 percent on a reported and constant currency basis, the company advised. Performance was driven by Miebo growth and increased sales in international pharmaceuticals. Miebo reported revenue grew 42 percent to $119 million in the quarter, while the dry eye portfolio saw overall revenue growth of 22 percent. Operating Results Operating income was $155 million for the third quarter of 2026, compared with operating income of $95 million for the third quarter of 2025, a favorable change of $60 million, the company stated. The change was driven by revenue growth and operating efficiencies. Net income attributable to Bausch + Lomb Corporation for the third quarter of 2026 was $32 million, compared with a $28 million loss for the third quarter of 2025, a favorable change of $60 million. Adjusted net income attributable to Bausch + Lomb Corporation (non-GAAP) for the third quarter of 2026 was $123 million, compared with adjusted net income attributable to Bausch + Lomb Corporation (non-GAAP) of $66 million for the third quarter of 2025, an increase of $57 million. Cash flow from operations for the third quarter of 2026 was $233 million, compared with cash flow from operations of $137 million for the third quarter of 2025, an increase of $96 million, the company stated. Adjusted EBITDA (non-GAAP) was $325 million for the third quarter of 2026, compared with $243 million for the third quarter of 2025, an increase of $82 million. The company also provided updated guidance for the full year of 2026. Full-year revenue is now expected to be in the range of $5.45 billion to $5.55 billion from $5.44 billion to $5.54 billion.

Bausch + Lomb (NYSE:BLCO) posts quarterly earnings results, beats expectations by $0.13 EPS. October 28, 2026 Key points. * Bausch + Lomb beat quarterly expectations: EPS was $0.34 versus the $0.21 consensus, while revenue reached $1.38 billion, up 7.3% year over year. * Management raised 2026 guidance for the third time, targeting revenue of $5.45 billion-$5.55 billion and adjusted EBITDA of $1.09 billion-$1.14 billion, supported by growth across all business segments. * Profitability and balance-sheet metrics improved: Adjusted EBITDA rose 34%, free cash flow reached $178 million, and net leverage fell to 4.1 times; the stock gained 8.6% following the results. * Interested in Bausch + Lomb? Here are five stocks we like better. Bausch + Lomb (NYSE:BLCO - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.13, FiscalAI reports. The firm had revenue of $1.38 billion for the quarter, compared to analyst estimates of $1.37 billion. During the same quarter in the prior year, the business posted $0.18 EPS. The business's revenue was up 7.3% on a year-over-year basis. Here are the key takeaways from Bausch + Lomb's conference call: * Strong third-quarter results: Constant-currency revenue rose 8% to $1.375 billion, adjusted EBITDA increased 34% to $325 million, and adjusted EBITDA margin expanded 460 basis points to 23.6%. * Management raised 2026 guidance for the third time, increasing revenue guidance to $5.45 billion-$5.55 billion and adjusted EBITDA guidance to $1.09 billion-$1.14 billion, implying approximately 20.3% full-year EBITDA margin. * Growth was broad-based across all segments, led by Pharmaceuticals at 11%, Surgical at 9%, and Vision Care at 6%; key products included MIEBO, LUMIFY, Daily SiHy contact lenses, and premium IOLs. * Cash generation strengthened, with $233 million of operating cash flow and $178 million of free cash flow, reducing net leverage to 4.1 times from 5.7 times a year earlier and keeping the company on track toward its 3.5-times target. * Tom Appio is serving as interim CEO following a mutually agreed leadership transition. He emphasized operational efficiency, disciplined capital allocation, debt reduction, and advancing the innovation pipeline, while providing limited detail on the reasons for the change. Bausch + Lomb trading up 8.6%. BLCO traded up $1.52 on Wednesday, reaching $19.14. The stock had a trading volume of 1,073,933 shares, compared to its average volume of 437,583. Bausch + Lomb has a fifty-two week low of $14.44 and a fifty-two week high of $19.44. The firm has a 50-day moving average of $17.18 and a 200-day moving average of $16.64. The company has a market capitalization of $6.84 billion, a price-to-earnings ratio of -40.23 and a beta of 0.56. Insider transactions at Bausch + Lomb. In related news, Director Eschenbach Andrew C. Von sold 6,059 shares of Bausch + Lomb stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $16.58, for a total transaction of $100,458.22. Following the sale, the director directly owned 63,733 shares in the company, valued at $1,056,693.14. This trade represents a 8.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Frederick Munsch sold 52,900 shares of the business's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $16.78, for a total transaction of $887,662.00. Following the sale, the chief accounting officer directly owned 45,831 shares in the company, valued at $769,044.18. The trade was a 53.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 71,459 shares of company stock worth $1,194,370 over the last three months. Insiders own 1.45% of the company's stock. Wall Street analyst weigh in. A number of research analysts have issued reports on the company. Weiss Ratings upgraded Bausch + Lomb from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, August 21st. Citigroup increased their target price on shares of Bausch + Lomb from $19.00 to $21.00 and gave the stock a "buy" rating in a report on Wednesday, July 8th. HC Wainwright restated a "buy" rating and issued a $21.00 price target on shares of Bausch + Lomb in a research note on Friday, August 28th. Leerink Partners began coverage on shares of Bausch + Lomb in a research note on Wednesday, September 9th. They issued an "outperform" rating and a $24.00 price target on the stock. Finally, UBS Group assumed coverage on shares of Bausch + Lomb in a report on Thursday, July 30th. They set a "buy" rating and a $21.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $19.46. Discover more MarketBeat All Access MarketBeat Research Tools Bausch + Lomb company profile. Bausch + Lomb Corporation NYSE: BLCO is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment. Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Bausch + Lomb, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch + Lomb wasn't on the list. While Bausch + Lomb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power. Continue following MarketBeat

What Bausch Health Cos (BHC) said on its Q3 earnings call. October 28, 2026 Key points. * Bausch Health raised its 2026 outlook for the second consecutive quarter, citing broad-based growth. Excluding Bausch + Lomb, third-quarter revenue rose 12% to $1.566 billion, while consolidated adjusted EBITDA increased 32% to $1.305 billion. * Salix and XIFAXAN drove quarterly performance, with Salix revenue up 16% to $831 million. However, channel-inventory normalization and a Medicare pricing-related accrual are expected to weigh heavily on fourth-quarter and 2027 results. * The company reduced net debt by $521 million in the quarter and more than $1 billion year to date. Bausch Health now expects 2026 revenue of $5.525 billion-$5.625 billion, adjusted EBITDA of $3.225 billion-$3.275 billion, and operating cash flow of $1.6 billion-$1.675 billion. * MarketBeat previews top five stocks to own in November. Bausch Health Cos NYSE: BHC raised its full-year 2026 outlook for the second consecutive quarter after reporting third-quarter growth across its operating segments, led by Salix and supported by international operations and Solta Medical. Excluding Bausch + Lomb, Bausch Health reported third-quarter revenue of $1.566 billion, up 12% from a year earlier, and adjusted EBITDA of $1.022 billion, which Chief Financial Officer J.J. Charhon described as the company's strongest quarterly performance since Bausch + Lomb's IPO. Adjusted cash flow from operations rose $192 million year over year to $539 million. On a consolidated basis, including Bausch + Lomb, revenue totaled $2.941 billion, up 10% on a reported basis and 8% organically. Consolidated adjusted EBITDA increased 32% to $1.305 billion, while adjusted cash flow from operations rose 54% to $782 million. Salix drives quarterly performance. Salix revenue rose 16% to $831 million during the quarter, driven principally by XIFAXAN. Charhon said the product benefited from favorable net realized pricing and continued demand, with retail prescriptions excluding Medicaid increasing 1.8% year over year. Quarterly new-to-brand patients rose by 1,800 sequentially. Charhon also noted that XIFAXAN volume growth in the quarter was aided by increased channel inventory. The company expects factors related to XIFAXAN to create headwinds in the fourth quarter. Specifically, Bausch Health expects to adjust its gross-to-net accrual tied to channel inventory ahead of a new XIFAXAN price for Medicare that takes effect Jan. 1, 2027. The company said the adjustment alone is expected to reduce fourth-quarter revenue growth by 800 basis points and adjusted EBITDA growth by 1,400 basis points. The company also expects some normalization in XIFAXAN channel inventory, which it said could reduce fourth-quarter revenue growth by at least an additional 300 basis points and adjusted EBITDA growth by 500 basis points. Discover more MarketBeat All Access MarketBeat Research Tools In response to an analyst question, Charhon said the gross-to-net accrual associated with the anticipated 2027 pricing change exceeds $100 million. He said the company has not provided specific details regarding the subsequent impact of the Medicare rebate, but indicated that its implied 2027 guidance of about $2.7 billion suggests an estimated $400 million to $500 million year-over-year impact from the combined factors. International and Solta results. The international segment generated $299 million in revenue, up 4% organically. The company cited contributions from its major geographies, including 3% organic growth in Europe, the Middle East and Africa, where Poland grew 7% and Hungary grew 32%. Latin America continued its return to growth, according to the company, as its top 10 products increased 18% organically. Bedoyecta, its largest brand in the region, increased 28% organically. Canada's organic revenue rose 7%, with promoted products led by RYALTRIS and CABTREO posting double-digit gains. Solta Medical reported revenue of $165 million, up 18% on a reported basis. Reported growth was led by Asia-Pacific markets, including a 66% increase in China and a 23% increase in Taiwan. Organic revenue declined 4% in the quarter, which management attributed to differing revenue phasing compared with the prior year and volatility related to tariffs on U.S. imports to China. For the first nine months of 2026, Solta revenue increased 34% on a reported basis and 8% organically. Chief Executive Officer Thomas Appio said the company views the year-to-date performance as a better reflection of Solta's operating trajectory. Appio said the integration of Solta's China distributor has progressed well, though consumer confidence and spending in China have softened and local and Korean competitors have entered the skin-tightening market. In Korea, consumables revenue rose 18%, even as equipment sales faced a more saturated market. U.S. revenue was approximately flat, while volume increased, he said. Charhon said Solta is expected to return to strong reported growth in the fourth quarter, aided by comparisons with the prior year. He said the company expects mid-single-digit organic growth for the segment in the fourth quarter. Cash flow, debt reduction and updated outlook. Bausch Health reduced net debt by $521 million during the third quarter and by more than $1 billion since the start of the year. The company ended the period with $2 billion in cash. Charhon said Bausch Health is evaluating capital-allocation actions, including early redemptions of its 2027 notes and up to $100 million in open-market repurchases of public debt. The company also announced a $50 million share repurchase program, primarily intended to offset dilution from anticipated management equity award vesting in 2027. For 2026, Bausch Health now expects: * Revenue of $5.525 billion to $5.625 billion, with the midpoint representing 8% year-over-year growth. * Adjusted EBITDA of $3.225 billion to $3.275 billion, with the midpoint representing 13% growth from 2025. * Adjusted cash flow from operations of $1.6 billion to $1.675 billion, with the midpoint representing 29% growth. Appio said the company remains focused on maximizing current portfolio performance, pursuing operational improvements, building its pipeline through internal development and business development, and maximizing value for Bausch + Lomb shareholders. Within research and development, Bausch Health said its Phase III program for larsucosterol in alcohol-associated hepatitis remains on track toward a potential 2029 approval, subject to successful clinical development and regulatory review. Chief Medical Officer and Head of Research and Development Jonathan Sadeh said the company does not currently see a need for an interim analysis, citing the study's six-month treatment period and the company's confidence in the Phase II data. About Bausch Health Cos (NYSE:BHC). Bausch Health Companies Inc NYSE: BHC is a multinational specialty pharmaceutical company focused on developing, manufacturing and commercializing branded, generic and over-the-counter medicines. Its portfolio serves several therapeutic areas, including gastroenterology, dermatology, neurology, ophthalmology, hospital products and other specialty-care markets. The company markets products through businesses such as Salix Pharmaceuticals, Ortho Dermatologics, Solta Medical and its international pharmaceutical operations. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Bausch Health Cos, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Cos wasn't on the list. While Bausch Health Cos currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you'll find 7 stocks that could play a major role in the next tech-driven market boom. Continue following MarketBeat